Form 4: Entrada Therapeutics CFO Kory James Wentworth Sells Shares
SEC Form 4 Filing
Kory James Wentworth, CFO of Entrada Therapeutics, sold 1,758 shares of common stock at a price of $14.95 on July 8, 2024, according to a Form 4 filing with the SEC.
Summary
- On July 8, 2024, Kory James Wentworth, the Chief Financial Officer of Entrada Therapeutics, sold 1,758 shares of common stock.
- The sale was executed at a price of $14.95 per share.
- Following the transaction, Wentworth directly owns 81,412 shares of Entrada Therapeutics.
- The sale was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 15, 2024.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it reports a routine stock sale by an executive under a pre-arranged trading plan. It doesn't inherently indicate positive or negative sentiment towards the company.
Industry Context
This is a routine disclosure of insider trading activity. It's common for executives to sell shares for personal financial management, especially under pre-arranged trading plans.
Stakeholder Impact
- The sale of shares by a company executive could be perceived negatively by some shareholders, although the existence of a 10b5-1 plan mitigates this concern.
Key Dates
| Date | Description |
|---|---|
| March 15, 2024 | Date of adoption of Rule 10b5-1 trading plan |
| July 08, 2024 | Date of stock sale transaction |
| July 10, 2024 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.